SFY Intrinsic Valuation and Fundamental Analysis - Theriva Biologics Inc - Alpha Spread

Theriva Biologics Inc
F:SFY

Watchlist Manager
Theriva Biologics Inc Logo
Theriva Biologics Inc
F:SFY
Watchlist
Price: 2.42 EUR Market Closed
Market Cap: 41.8m EUR
Have any thoughts about
Theriva Biologics Inc?
Write Note

Intrinsic Value

SFY's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one SFY stock under the Base Case scenario is 0.94 EUR. Compared to the current market price of 2.42 EUR, Theriva Biologics Inc is Overvalued by 61%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SFY Intrinsic Value
0.94 EUR
Overvaluation 61%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Theriva Biologics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SFY based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about SFY?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Theriva Biologics Inc

Provide an overview of the primary business activities
of Theriva Biologics Inc.

What unique competitive advantages
does Theriva Biologics Inc hold over its rivals?

What risks and challenges
does Theriva Biologics Inc face in the near future?

Summarize the latest earnings call
of Theriva Biologics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Theriva Biologics Inc.

Provide P/S
for Theriva Biologics Inc.

Provide P/E
for Theriva Biologics Inc.

Provide P/OCF
for Theriva Biologics Inc.

Provide P/FCFE
for Theriva Biologics Inc.

Provide P/B
for Theriva Biologics Inc.

Provide EV/S
for Theriva Biologics Inc.

Provide EV/GP
for Theriva Biologics Inc.

Provide EV/EBITDA
for Theriva Biologics Inc.

Provide EV/EBIT
for Theriva Biologics Inc.

Provide EV/OCF
for Theriva Biologics Inc.

Provide EV/FCFF
for Theriva Biologics Inc.

Provide EV/IC
for Theriva Biologics Inc.

Show me price targets
for Theriva Biologics Inc made by professional analysts.

What are the Revenue projections
for Theriva Biologics Inc?

How accurate were the past Revenue estimates
for Theriva Biologics Inc?

What are the Net Income projections
for Theriva Biologics Inc?

How accurate were the past Net Income estimates
for Theriva Biologics Inc?

What are the EPS projections
for Theriva Biologics Inc?

How accurate were the past EPS estimates
for Theriva Biologics Inc?

What are the EBIT projections
for Theriva Biologics Inc?

How accurate were the past EBIT estimates
for Theriva Biologics Inc?

Compare the revenue forecasts
for Theriva Biologics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Theriva Biologics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Theriva Biologics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Theriva Biologics Inc compared to its peers.

Compare the P/E ratios
of Theriva Biologics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Theriva Biologics Inc with its peers.

Analyze the financial leverage
of Theriva Biologics Inc compared to its main competitors.

Show all profitability ratios
for Theriva Biologics Inc.

Provide ROE
for Theriva Biologics Inc.

Provide ROA
for Theriva Biologics Inc.

Provide ROIC
for Theriva Biologics Inc.

Provide ROCE
for Theriva Biologics Inc.

Provide Gross Margin
for Theriva Biologics Inc.

Provide Operating Margin
for Theriva Biologics Inc.

Provide Net Margin
for Theriva Biologics Inc.

Provide FCF Margin
for Theriva Biologics Inc.

Show all solvency ratios
for Theriva Biologics Inc.

Provide D/E Ratio
for Theriva Biologics Inc.

Provide D/A Ratio
for Theriva Biologics Inc.

Provide Interest Coverage Ratio
for Theriva Biologics Inc.

Provide Altman Z-Score Ratio
for Theriva Biologics Inc.

Provide Quick Ratio
for Theriva Biologics Inc.

Provide Current Ratio
for Theriva Biologics Inc.

Provide Cash Ratio
for Theriva Biologics Inc.

What is the historical Revenue growth
over the last 5 years for Theriva Biologics Inc?

What is the historical Net Income growth
over the last 5 years for Theriva Biologics Inc?

What is the current Free Cash Flow
of Theriva Biologics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Theriva Biologics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Theriva Biologics Inc

Current Assets 21.7m
Cash & Short-Term Investments 18.3m
Receivables 1.9m
Other Current Assets 1.5m
Non-Current Assets 27.1m
PP&E 21.3m
Intangibles 5.6m
Other Non-Current Assets 176k
Current Liabilities 6m
Accounts Payable 571k
Accrued Liabilities 4.5m
Other Current Liabilities 948k
Non-Current Liabilities 8.6m
Long-Term Debt 159k
Other Non-Current Liabilities 8.4m
Efficiency

Earnings Waterfall
Theriva Biologics Inc

Revenue
0 USD
Operating Expenses
-21.6m USD
Operating Income
-21.6m USD
Other Expenses
2.6m USD
Net Income
-19m USD

Free Cash Flow Analysis
Theriva Biologics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SFY Profitability Score
Profitability Due Diligence

Theriva Biologics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Theriva Biologics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

SFY Solvency Score
Solvency Due Diligence

Theriva Biologics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
65/100
Solvency
Score

Theriva Biologics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SFY Price Targets Summary
Theriva Biologics Inc

Wall Street analysts forecast SFY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SFY is 2.74 EUR with a low forecast of 0.68 EUR and a high forecast of 4.94 EUR.

Lowest
Price Target
0.68 EUR
72% Downside
Average
Price Target
2.74 EUR
13% Upside
Highest
Price Target
4.94 EUR
104% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SFY?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for SFY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about SFY dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

SFY Price
Theriva Biologics Inc

1M 1M
-35%
6M 6M
-76%
1Y 1Y
-82%
3Y 3Y
-97%
5Y 5Y
-98%
10Y 10Y
-100%
Annual Price Range
2.42
52w Low
0.1616
52w High
14
Price Metrics
Average Annual Return -36.48%
Standard Deviation of Annual Returns 31.78%
Max Drawdown -100%
Shares Statistics
Market Capitalization 41.5m EUR
Shares Outstanding 17 277 400
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

Theriva Biologics Inc Logo
Theriva Biologics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

41.5m EUR

Dividend Yield

0%

Description

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 21 full-time employees. The firm is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patients immune system. The Company’s lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Contact

MARYLAND
Rockville
9605 Medical Center Drive, Suite 270
+17343327800
therivabio.com

IPO

1993-02-12

Employees

21

Officers

See Also

Discover More
What is the Intrinsic Value of one SFY stock?

The intrinsic value of one SFY stock under the Base Case scenario is 0.94 EUR.

Is SFY stock undervalued or overvalued?

Compared to the current market price of 2.42 EUR, Theriva Biologics Inc is Overvalued by 61%.

Back to Top